Daré Bioscience said it expects top-line data for its Ovaprene contraceptive candidate in 2027 and plans to begin dispensing its DARE to PLAY Sildenafil Cream this quarter. The company launched Flora Sync LF5 in June, the first product in its DARE to RESTORE line, and reported positive interim results for Ovaprene with a Data Safety Monitoring Board recommendation to continue the study without modification. Daré expects to enroll sufficient subjects in 2026 to achieve at least 2,500 menstrual cycles of exposure in 2027, supporting the top-line data announcement. The FDA approved a protocol amendment to remove the expectation of 250 completers, though the agency continued to strongly recommend that minimum. Daré ended the quarter with approximately $12.6 million in cash and cash equivalents as of June 30, 2026, and a working capital deficit of approximately $0.2 million.
Dare Bioscience IncPositive interim results for Ovaprene and FDA protocol amendment support progress, though top-line data delayed to 2027.
